ERBB2 and endometrial serous adenocarcinoma: In mouse models of uterine serous carcinoma, combined ridaforolimus and HER2 blockade with lapatinib/trastuzumab had a better anti-tumor activity when tumors had PIK3CA (E542K) mutations together with HER2 gene amplification rather than those without PIK3CA mutations.